


IN THE CLAIMS

Claims 1-24. (canceled)

Claim 25. (new) A method of treating a Chlamydia infection in a patient, the method comprises the step of administering to the patient a therapeutically effective amount of an immunogenic protein, wherein the immunogenic protein is ribosomal protein L7/L12, a homologue of ribosomal protein L7/L12, or a fragment of ribosomal protein L7/L12.

Claim 26. (new) The method of claim 25 wherein the immunogenic protein is ribosomal protein L7/L12.

 Claim 27. (new) The method of claim 26 wherein the protein has the MW and pI characteristics of protein 12 (as set out in Table II on page 15).

Claim 28. (new) The method of claim 26 wherein the protein has an N-terminal amino acid sequence disclosed in Table III on page 16.

Claim 29. (new) The method of claim 25 wherein the protein is a fragment of ribosomal protein L7/L12.

Claim 30. (new) The method of claim 29 wherein the fragment has the MW and pI characteristics of a fragment of protein 12 (as set out in Table II on page 15).

Claim 31. (new) The method of claim 29 wherein the fragment comprises at least 7 consecutive amino acids of the protein.

Claim 32. (new) The method of claim 25 wherein the immunogenic protein is a homologue of ribosomal protein L7/L12.

Claim 33. (new) The method of claim 32 wherein the homologue has greater than 50% identity to ribosomal protein L7/L12.

Claim 34. (new) The method of claim 33 wherein the homologue has greater than 90% identity to ribosomal protein L7/L12.

Claim 35. (new) The method of claim 32 wherein the homologue has the MW and pI characteristics of protein 12 (as set out in Table II on page 15).

Claim 36. (new) The method of claim 32 wherein the homologue has an N-terminal amino acid sequence disclosed in Table III on page 16.

Claim 37. (new) A method of preventing a Chlamydia infection in a patient, the method comprises the step of administering to the patient a prophylactically effective amount of an immunogenic protein, wherein the immunogenic protein is ribosomal protein L7/L12, a homologue of ribosomal protein L7/L12, or a fragment of ribosomal protein L7/L12.

Claim 38. (new) The method of claim 37 wherein the protein is ribosomal protein L7/L12.

Claim 39. (new) The method of claim 38 wherein the protein has the MW and pI characteristics of protein 12 (as set out in Table II on page 15).

Claim 40. (new) The method of claim 38 wherein the protein has an N-terminal amino acid sequence disclosed in Table III on page 16.

Claim 41. (new) The method of claim 37 wherein the immunogenic protein is a fragment of ribosomal protein L7/L12.

Claim 42. (new) The method of claim 41 wherein the fragment has the MW and pI characteristics of a fragment of protein 12 (as set out in Table II on page 15).

Claim 43. (new) The method of claim 41 wherein the fragment comprises at least 7 consecutive amino acids of the protein.

Claim 44. (new) The method of claim 37 wherein the immunogenic protein is a homologue of ribosomal protein L7/L12.

Claim 45. (new) The method of claim 44 wherein the homologue has greater than 50% identity to ribosomal protein L7/L12.

Claim 46. (new) The method of claim 45 wherein the homologue has greater than 90% identity to ribosomal protein L7/L12.

Claim 47. (new) The method of claim 44 wherein the homologue has the MW and pI characteristics of protein 12 (as set out in Table II on page 15).

Claim 48. (new) The method of claim 44 wherein the homologue has an N-terminal amino acid sequence disclosed in Table III on page 16.
